In early-stage DCM, characterized by impaired calcium uptake and bioenergetic deficit, strategies to augment physiological uptake (e.g., via AMPK/PGC-1α activation) or stabilize the MCU complex might be beneficial. The gene discussed is PPARGC1A; the disease is familial dilated cardiomyopathy.